ELVN NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Enliven Therapeutics Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 54.81 USD
3.5% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 41.6% above the Trend Line and sits at 97.6% of its 52-week range. The latest completed week returned 3.5%, after a 10.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 29/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal; earnings are due in 10d.

Setup score 64 out of 100
Latest Close 54.81 USD 31 Jul 2026
1W Return 3.5% latest completed week
4W Return 10.0% short-term follow-through
12W Return 34.5% quarterly tape
Trend Breadth 78.8% 41 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 29-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 44.09% based on similar historical setup states.
  • 12 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 3.5% Latest completed week; four-week move 10.0%. Indicator stack 88/51 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 44.09% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Mixed 29/100 conviction; expected move 10.6%. News sentiment 53/100 55 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 41.6% above the Trend Line and sits at 97.6% of its 52-week range. The latest completed week returned 3.5%, after a 10.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8912-week average 0.91

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.89Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1212 reversal markers

No recent accumulation markers. 12 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 10.0% over four weeks, 34.5% over 12 weeks, and 192.6% over one year. The current trend has remained active for 29 consecutive weeks.

Performance by holding period

1W3.5%
4W10.0%
12W34.5%
26W107.2%
52W192.6%
Active trend streak29 weeks
Active weeks in one year41
Trend breadth78.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.26Latest activity-pressure read.
Pressure change-46.0%Four-week change in activity pressure.
Leadership66.79Latest relative-leadership reading.
RS change19.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength81/100Blend of value, momentum, and quality. Underlying universe rank 20; rank 1 is best.
Value65/100Relative valuation strength. Underlying universe rank 36; rank 1 is best.
Quality64/100Profitability and accounting quality. Underlying universe rank 37; rank 1 is best.
Momentum65/100Medium-term price momentum. Underlying universe rank 36; rank 1 is best.
Growth65/100Revenue and earnings growth. Underlying universe rank 36; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-23.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-5.7%
Net share repurchases relative to market value.
Shareholder yield
-5.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

ELVN shows mixed options pressure with a 29/100 conviction score, put-call volume ratio of n/a, expected move of 10.6%, and Sharemaestro trend signal active.

Conviction29/100
Expected move10.6%
Put/call volume
Pressure1
Speculation0
Volatility74
Trend agreement81
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 55 relevant articles.

11 positive · 37 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move10.6%Nearest-chain priced movement where available.
52-week drawdown-1.8%Distance below the 52-week high.
13-week volatility10.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2612 weeks finished lower.
Best week+33.8%Week of 27 Mar.
Worst week-12.3%Week of 5 Jun.
Latest week+3.5%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains4
Flat weeks1
Modest losses6
Sharp losses6
Recent vol10.2%13-week weekly-return volatility.
Base vol13.8%52-week weekly-return volatility.
Up/down split25/26Count of positive and negative weeks in the 52-week window.
Average skew11.5% / -5.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape61/100

Trend, activity pressure, participation, and risk combine to a 61/100 tape read.

 Indicator analysis81/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.89; 12 reversal markers Next-Week ExpectancyNegative 44.09%

Next-week expectancy is negative with a 44.09% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors68/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 83; Small Cap Core rank 44 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options53/100

ELVN shows mixed options pressure with a 29/100 conviction score, put-call volume ratio of n/a, expected move of 10.6%, and Sharemaestro trend signal active.

Mixed · Options-market disagreement · Expected move 10.6% Sentiment53/100

Weighted news tone is neutral across 55 relevant articles.

Trading Systems Reacting to (ELVN) Volatility Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202654.81 USD3.5%38.71 USD23.26 USD0.2666.794.3MOn
24 Jul 202652.95 USD-0.5%37.40 USD23.03 USD0.1365.052.7MOn
17 Jul 202653.20 USD4.1%36.17 USD22.81 USD0.3165.893.5MOn
10 Jul 202651.09 USD2.5%34.96 USD22.59 USD0.3655.015.5MOn
3 Jul 202649.82 USD-0.5%33.82 USD22.38 USD0.4855.865.6MOn
26 Jun 202650.08 USD11.0%32.89 USD22.17 USD0.3260.2516.9MOn
19 Jun 202645.10 USD-2.2%31.94 USD21.98 USD0.1439.8310.2MOn
12 Jun 202646.13 USD32.9%31.16 USD21.83 USD0.2148.1815.2MOn
5 Jun 202634.71 USD-12.3%30.36 USD21.67 USD0.2315.215.4MOn
29 May 202639.57 USD-4.7%29.79 USD21.58 USD0.5825.992.1MOn
22 May 202641.54 USD0.5%29.25 USD21.47 USD0.8537.293.3MOn
15 May 202641.34 USD1.4%28.55 USD21.33 USD1.0739.924.1MOn
8 May 202640.75 USD-2.3%27.89 USD21.19 USD1.3639.132.4MOn
1 May 202641.70 USD-5.8%27.23 USD21.05 USD1.6251.583.1MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.